We put inspiration into practice, finding viable solutions to complex challenges.
Great ideas are our starting point.
Research focus
curATalk Seminar Series
Within our curATime seminar series, Prof. Christoph Binder from the University of Vienna will give a presentation about „Humoral“ Immunity and Immune Homeostasis in Atherosclerosis on 23rd of November at 5 pm. Prof. Binder's research focuses on the immune mechanisms of atherosclerosis and the immune recognition of oxidation-specific epitopes and how these responses can be exploited to protect from atherosclerotic lesion formation.
We are TRON
TRON is an independent non-profit translational research organization. We pursue new diagnostics and drugs for the treatment of diseases with high medical need. We apply our transdisciplinary competencies in genomics and immunology to develop novel platforms for the identification and validation of ‘omics’-based biomarkers, to modulate immune system components for use in personalized therapies. Collaborating with academia and industry, TRON executes research at the leading edge to support innovative drug design for human health.
Our Research Focus
TRON conducts collaborative research on disease genomics and therapeutic modulation of the immune system. Specializing in cancer immunology and genomics, our research teams develop tailored bioinformatic and novel biostatistical approaches to identify and characterize disease-relevant molecular targets. We design and improve cutting edge technologies for biomarker discovery and biopharmaceutical development, including platforms for immune-based therapies such as RNA vaccines and cellular therapies.
Target Discovery and Validation
Personalized Therapy Development
Preclinical Vaccine Development
Cellular Therapy Development
Supported by
